ZBTB7B

ZBTB7B (ThPOK/c-Krox) is a BTB-POZ and zinc finger transcription factor that binds GC-rich promoter elements to either activate or repress target genes, governing extracellular matrix production, T cell lineage commitment, and adipocyte and tumor metabolic programs (PMID:8702912, PMID:17878336). Its zinc finger and C-terminal domains carry transactivation activity while the POZ domain mediates homo- and heterodimerization with related family members (PMID:8702912, PMID:11691585), and DNA recognition depends on base contacts made by the first zinc finger, since the R367Q mutation abolishes major-groove binding and collapses CD4 T cell development (PMID:31792077). In matrix-producing cells it directly occupies the COL1A1 and other collagen, fibronectin, and elastin promoters, cooperating with Sp1/Sp3 and acting as a docking platform that recruits NF-κB p65 to repress collagen transcription (PMID:11691585, PMID:15982635, PMID:22139845). In the immune system it promotes CD4 expression by antagonizing Runx1/Runx3-mediated repression and controls the effector balance of NKT cells, with BTB-POZ domain mutation skewing them toward an IL-17-producing RORγt+ phenotype (PMID:17878336, PMID:23105140). ZBTB7B also acts beyond classical transcription: it recruits the Blnc1/hnRNPU ribonucleoprotein complex to drive the brown/beige adipocyte thermogenic program (PMID:28784777) and recruits the m6A demethylase ALKBH5 to IL6 mRNA to limit its nuclear export (PMID:32828308). In cancer contexts it directly represses c-Jun to maintain adult hepatocyte identity and restrain HCC initiation (PMID:38225233), activates the glycolytic genes LDHA and ADPGK (PMID:39107297, PMID:41807371), suppresses the lncRNA H19 to limit hepatic lipogenesis (PMID:39714087), and restricts breast cancer EMT by repressing WNT and TGFβ programs (PMID:41231242). Its protein level and activity are tuned post-translationally by SUMOylation, which stabilizes its transcriptional activity (PMID:39107297), and by NEDD4-mediated ubiquitination at K450, which targets it for proteasomal degradation (PMID:41807371).

1. 1996 High

   Established ZBTB7B as a sequence-specific DNA-binding transcription factor for GC-rich elements and localized its functional domains, defining the molecular basis of its transcriptional activity.

   Evidence EMSA, reporter assays, and structure-function mutagenesis on collagen alpha1(I)/alpha2(I) promoters

   PMID:8702912

   Open questions at the time

   • Did not establish whether the factor activates or represses in physiological context
   • No genome-wide binding map
   • Endogenous target repertoire unknown
2. 2001 Medium

   Showed ZBTB7B functions as a repressor of multiple ECM genes and dimerizes through its POZ and zinc-finger regions, framing it as a multimeric transcriptional regulator of matrix gene expression.

   Evidence Reporter assays, EMSA, and co-immunoprecipitation of hcKrox isoforms

   PMID:11691585

   Open questions at the time

   • Dimer composition in vivo not defined
   • Single lab
   • Cofactors mediating repression not identified at this stage
3. 2011 High

   Resolved how ZBTB7B represses COL1A1 by binding the proximal promoter and recruiting NF-κB p65 via Sp1/Sp3, establishing a protein-interaction-based mechanism for matrix gene repression.

   Evidence ChIP, re-ChIP, co-IP, siRNA knockdown, and reporter assays in scleroderma fibroblasts

   PMID:22139845

   Open questions at the time

   • Structural basis of the multiprotein complex unresolved
   • Generality beyond collagen promoters not tested
4. 2007 High

   Defined the developmental logic by which ZBTB7B drives CD4 T cell commitment, showing it antagonizes Runx-mediated CD4 repression through an HDAC-sensitive transcriptional mechanism.

   Evidence In vitro reporter assays, in vivo mouse genetics, HDAC inhibitor treatment, and domain-function analysis across Runx1/Runx3

   PMID:17878336

   Open questions at the time

   • Direct targets cooperating with Runx not fully enumerated
   • Precise chromatin mechanism of antagonism unresolved
5. 2012 High

   Demonstrated that the BTB-POZ domain is required for ZBTB7B control of NKT effector subset balance, linking a specific domain to in vivo lineage and cytokine outcomes.

   Evidence BTB-POZ domain missense mutant mouse, flow cytometry, and cytokine profiling

   PMID:23105140

   Open questions at the time

   • Molecular partners engaged by the BTB-POZ domain in NKT cells not identified
   • Target genes driving the IL-17 vs IFN-γ switch not mapped
6. 2017 High

   Extended ZBTB7B function beyond classical transcription by showing it recruits a Blnc1/hnRNPU ribonucleoprotein complex to activate the thermogenic gene program in brown/beige fat.

   Evidence Genome-wide screen, knockout mice, proteomic identification of partners, and cold-challenge phenotyping

   PMID:28784777

   Open questions at the time

   • How the lncRNP complex is targeted to thermogenic loci is unresolved
   • Direct DNA-binding contribution vs RNP scaffolding not separated
7. 2020 Medium

   Revealed a post-transcriptional role in which ZBTB7B recruits ALKBH5 to demethylate IL6 mRNA and block its nuclear export, implicating it in m6A-dependent RNA regulation.

   Evidence siRNA knockdown, RNA co-IP, m6A quantification, and nuclear export assays

   PMID:32828308

   Open questions at the time

   • Single lab, single study
   • Direct vs indirect ZBTB7B-ALKBH5-mRNA recruitment not structurally defined
   • Breadth of mRNA targets unknown
8. 2020 High

   Pinpointed the first zinc finger as the determinant of DNA recognition and provided a genome-wide map of ThPOK chromatin occupancy in T cell lineage specification.

   Evidence ENU mutagenesis (R367Q), structural prediction, ChIP-seq, and in vivo immune phenotyping

   PMID:31792077

   Open questions at the time

   • Full target network not functionally validated
   • Cofactor composition at occupied sites not resolved
9. 2024 High

   Established ZBTB7B as a guardian of adult hepatocyte identity that directly represses and competes with c-Jun, restraining HCC initiation.

   Evidence Hepatocyte-specific knockout, multi-omics (transcriptomic, phosphoproteomic, ChIP-seq), reporter assays, and c-Jun knockdown rescue

   PMID:38225233

   Open questions at the time

   • Mechanism of chromatin competition with c-Jun not structurally defined
   • Upstream signals controlling ZBTB7B in liver unclear
10. 2024 Medium

    Linked ZBTB7B to glycolytic and lipid metabolic control in cancer, showing it activates LDHA (stabilized by SUMOylation) and suppresses lncRNA H19 to limit hepatic lipogenesis.

    Evidence Luciferase reporter, ChIP-qPCR, RNA-seq, SUMOylation assay, and liver-specific knockout metabolic phenotyping

    PMID:39107297 PMID:39714087

    Open questions at the time

    • SUMOylation site and machinery not mapped
    • Mechanism of H19 suppression not detailed
    • Single lab per study
11. 2025 Medium

    Showed ZBTB7B physically engages the androgen receptor NTD and restricts AR-driven and EMT programs, broadening its repressive role to additional cancer contexts.

    Evidence Co-IP, immunofluorescence, cycloheximide chase, ubiquitination assays, domain mapping; and super-enhancer profiling with ThPOK manipulation in breast cancer lines

    PMID:41231242 PMID:41378003

    Open questions at the time

    • Whether AR effects are transcriptional vs stability-based not fully separated
    • Direct DNA targets in EMT repression not mapped
    • Single lab per study
12. 2026 Medium

    Defined post-translational control of ZBTB7B stability by NEDD4-mediated K450 ubiquitination and linked ZBTB7B to activation of metabolic (ADPGK, GPR17) and immune-infiltration (CXCL10) programs in tumors.

    Evidence Reporter assays, ChIP, co-IP, site-specific ubiquitination mutagenesis (K450), lentiviral overexpression, and in vitro/xenograft tumor models

    PMID:41294275 PMID:41807371

    Open questions at the time

    • Directness of GPR17/CXCL10 transcriptional activation not fully elaborated
    • Signals regulating NEDD4-ZBTB7B in vivo unclear
    • Single lab per study

• How ZBTB7B switches between activator, repressor, and RNA/m6A-regulatory modes across tissues remains unresolved.
• No unified model linking cofactor selection to activation vs repression
• Structural basis of partner choice (Sp1/Sp3, p65, hnRNPU, ALKBH5, AR) unknown
• Integration of SUMO and NEDD4 post-translational control with context-specific outputs undefined